LCM
BEAM icon

Laurion Capital Management’s Beam Therapeutics BEAM Stock Holding History

Laurion Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-25,000
Closed -$2M – 721
2021
Q1 		$2M Hold
25,000
– – 0.01% 426
2020
Q4 		$2.04M Hold
25,000
– – 0.02% 341
2020
Q3 		$616K Hold
25,000
– – 0.01% 537
2020
Q2 		$700K Hold
25,000
– – 0.01% 540
2020
Q1 		$450K Buy
+25,000
New +$543K ﹤0.01% 594

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Laurion Capital Management's BEAM Position: Q2 2021 in Review

Laurion Capital Management sold out of Beam Therapeutics (BEAM) in Q2 2021, closing a stake of 25,000 shares — an estimated $2M sold.

Laurion Capital Management first reported a position in BEAM in Q1 2020 and held it in 5 quarters. The position peaked at $2.04M in Q4 2020. 231 funds tracked by Wall St. Rank hold BEAM as of Q2 2021.

  • Laurion Capital Management reported no remaining Beam Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Laurion Capital Management sold 25,000 Beam Therapeutics shares in Q2 2021, an estimated $2M.
  • Laurion Capital Management first reported a position in Beam Therapeutics in Q1 2020 and held it in 5 quarters.
  • Laurion Capital Management's Beam Therapeutics position peaked at $2.04M in Q4 2020.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2021.

Based on Laurion Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.